79 related articles for article (PubMed ID: 20182727)
1. Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies.
Kiewe P; Neumann M; Wagner T; Seyfert S; Albrecht H; Thiel E; Korfel A
Cancer Chemother Pharmacol; 2011 Jan; 67(1):27-33. PubMed ID: 20182727
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys.
Arndt CA; Balis FM; McCully CL; Colvin OM; Poplack DG
Cancer Res; 1988 Apr; 48(8):2113-5. PubMed ID: 3349482
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
5. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
6. CXCL13 and CXCL12 in central nervous system lymphoma patients.
Fischer L; Korfel A; Pfeiffer S; Kiewe P; Volk HD; Cakiroglu H; Widmann T; Thiel E
Clin Cancer Res; 2009 Oct; 15(19):5968-73. PubMed ID: 19773382
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention.
Lokiec F
Ann Oncol; 2006 May; 17 Suppl 4():iv33-6. PubMed ID: 16702183
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Wagner T; Bechrakis NE; Willerding G; Coupland SE; Fischer L; Thiel E; Korfel A
Ann Oncol; 2005 Dec; 16(12):1974-8. PubMed ID: 16219622
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Yule SM; Price L; Pearson AD; Boddy AV
Clin Cancer Res; 1997 Nov; 3(11):1985-92. PubMed ID: 9815588
[TBL] [Abstract][Full Text] [Related]
11. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
Brain EG; Rezai K; Weill S; Gauzan MF; Santoni J; Besse B; Goupil A; Turpin F; Urien S; Lokiec F
Cancer Chemother Pharmacol; 2007 Aug; 60(3):375-81. PubMed ID: 17106751
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic considerations in the treatment of CNS tumours.
Motl S; Zhuang Y; Waters CM; Stewart CF
Clin Pharmacokinet; 2006; 45(9):871-903. PubMed ID: 16928151
[TBL] [Abstract][Full Text] [Related]
13. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
[TBL] [Abstract][Full Text] [Related]
14. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
Brüggemann SK; Pfäffle S; Peters SO; Wagner T
Drug Metab Dispos; 2007 Oct; 35(10):1721-4. PubMed ID: 17600085
[TBL] [Abstract][Full Text] [Related]
15. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken JB
Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
17. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies.
Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A
Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioavailability of stereoisomeric analogues of ifosfamide.
Sloderbach A; Hładoń B; Laskowska H
Acta Physiol Hung; 1996; 84(4):459-60. PubMed ID: 9328631
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of potential metabolites of (S)-(-)-bromofosfamide.
Misiura K
Pharmazie; 2004 Sep; 59(9):668-72. PubMed ID: 15497745
[TBL] [Abstract][Full Text] [Related]
20. Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans.
Preiss R; Baumann F; Stefanovic D; Niemeyer U; Pönisch W; Niederwieser D
Cancer Chemother Pharmacol; 2004 Jun; 53(6):496-502. PubMed ID: 15138712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]